Trials / Completed
CompletedNCT00103467
Trial to Evaluate the Safety and Immunogenicity of an Anthrax Recombinant Protective Antigen Vaccine
A Phase 1 Trial to Evaluate the Safety and Immunogenicity of an Anthrax Recombinant Protective Antigen Vaccine
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 100 (planned)
- Sponsor
- VaxGen · Industry
- Sex
- All
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this phase 1 study is to evaluate the safety and immunogenicity of rPA102 vaccine, using anthrax vaccine adsorbed (AVA) as a comparator.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | rPA102 Vaccine |
Timeline
- Start date
- 2003-06-01
- First posted
- 2005-02-09
- Last updated
- 2005-06-24
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00103467. Inclusion in this directory is not an endorsement.